Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 23;218(7):2113–2123. doi: 10.1083/jcb.201808134

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Chen et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 3. — ATR inhibition leads to DDR in Xlf^−/− cells. (A) Cell lysates from Xlf^−/− MEFs treated with ATRi for the indicated times were analyzed by Western blotting using the indicated antibodies. (B) Cell lysates from Xlf^−/− MEFs transduced with Control (shCT) or RAD51 (shRAD51) shRNAs and treated with ATRi for 8 h were analyzed by Western blotting using the indicated antibodies. (C) Cell lysates from Xlf⁻^/⁻ MEFs untreated or pretreated with ATMi or DNA-PKcsi for 30 min before treatment with ATRi for 8 h were analyzed by Western blotting using the indicated antibodies. (D) Western blot analysis of whole cell lysates from WT and Xrcc4^−/− MEFs treated with ATRi for indicated times using the indicated antibodies. (E) Cell viability of WT, Xlf⁻^/⁻, or Xrcc4^−/− MEFs treated with the ATRi at indicated concentrations for 4 d. Error bars indicating SD of three technical repeats from a representative experiment from analyses of two independent cell lines of each genotype analyzed in two experiments, each in triplicate.